Physician profile
John E Shockley
NPI 1639161003
$3,816.01
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $545 · 2021: $1,220 · 2022: $1,060 · 2023: $17.25 · 2024: $17.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $307.57 | 2019-2022 | |
| Novo Nordisk INC | $301.62 | 2019-2024 | |
| Pfizer INC. | $289.55 | 2019-2022 | |
| Lilly USA, LLC | $274.18 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $239.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.67 | 2019-2022 | |
| Amarin Pharma, INC. | $165.32 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $153.05 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $143.90 | 2022 | |
| Allergan, INC. | $142.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.36 | 2019-2021 | |
| Abbott Laboratories | $92.32 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $88.06 | 2020-2021 | |
| Amgen INC. | $86.16 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $74.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.83 | 2019-2021 | |
| Eisai INC. | $43.63 | 2020-2021 | |
| Daiichi Sankyo INC. | $41.01 | 2019-2022 | |
| Astellas Pharma US INC | $32.84 | 2019 | |
| Shire North American Group INC | $32.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.16 | 2019 | |
| Genentech USA, INC. | $24.42 | 2019-2020 | |
| Antares Pharma, INC. | $23.60 | 2019 | |
| Almatica Pharma LLC | $21.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2022 | |
| Bausch Health US, LLC | $15.69 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.70 | 2021 | |
| Medtronic, INC. | $14.64 | 2022 | |
| Nevro Corp. | $13.79 | 2021 | |
| Therapeuticsmd, INC. | $12.93 | 2019 | |
| Boston Scientific Corporation | $12.44 | 2020 | |
| Sanofi Pasteur INC. | $12.30 | 2019 | |
| Zyla Life Sciences, INC. | $11.79 | 2019 | |
| Vistapharm, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shockley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.